{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T13:36:21Z","timestamp":1791984981901,"version":"4.4.0"},"reference-count":129,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T00:00:00Z","timestamp":1623024000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Deputyship for Research &amp; Innovation, Ministry of Education, Saudi Arabia","award":["IFKSURG-1441-443"],"award-info":[{"award-number":["IFKSURG-1441-443"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Cancer is one of the major leading causes of mortality in the world. The implication of nanotherapeutics in cancer has garnered splendid attention owing to their capability to efficiently address various difficulties associated with conventional drug delivery systems such as non-specific biodistribution, poor efficacy, and the possibility of occurrence of multi-drug resistance. Amongst a plethora of nanocarriers for drugs, this review emphasized lipidic nanocarrier systems for delivering anticancer therapeutics because of their biocompatibility, safety, high drug loading and capability to simultaneously carrying imaging agent and ligands as well. Furthermore, to date, the lack of interaction between diagnosis and treatment has hampered the efforts of the nanotherapeutic approach alone to deal with cancer effectively. Therefore, a novel paradigm with concomitant imaging (with contrasting agents), targeting (with biomarkers), and anticancer agent being delivered in one lipidic nanocarrier system (as cancer theranostics) seems to be very promising in overcoming various hurdles in effective cancer treatment. The major obstacles that are supposed to be addressed by employing lipidic theranostic nanomedicine include nanomedicine reach to tumor cells, drug internalization in cancer cells for therapeutic intervention, off-site drug distribution, and uptake via the host immune system. A comprehensive account of recent research updates in the field of lipidic nanocarrier loaded with therapeutic and diagnostic agents is covered in the present article. Nevertheless, there are notable hurdles in the clinical translation of the lipidic theranostic nanomedicines, which are also highlighted in the present review along with plausible countermeasures.<\/jats:p>","DOI":"10.3390\/pharmaceutics13060840","type":"journal-article","created":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T22:23:00Z","timestamp":1623104580000},"page":"840","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":95,"title":["Recent Progress in Lipid Nanoparticles for Cancer Theranostics: Opportunity and Challenges"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6002-9249","authenticated-orcid":false,"given":"Sarah I.","family":"Bukhari","sequence":"first","affiliation":[{"name":"Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8913-0826","authenticated-orcid":false,"given":"Syed Sarim","family":"Imam","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2979-8776","authenticated-orcid":false,"given":"Mohammad Zaki","family":"Ahmad","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, College of Pharmacy, Najran University, Najran 11001, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parameswara Rao","family":"Vuddanda","sequence":"additional","affiliation":[{"name":"Research Centre for Topical Drug Delivery and Toxicology (TDDT), University of Hertfordshire, Hertfordshire AL10 9AB, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0922-9819","authenticated-orcid":false,"given":"Sultan","family":"Alshehri","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia"},{"name":"Department of Pharmaceutical Sciences, College of Pharmacy, Almaarefa University, Riyadh 11597, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7083-1753","authenticated-orcid":false,"given":"Wael A.","family":"Mahdi","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7025-751X","authenticated-orcid":false,"given":"Javed","family":"Ahmad","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, College of Pharmacy, Najran University, Najran 11001, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,6,7]]},"reference":[{"key":"ref_1","unstructured":"Ferlay, J., Laversanne, M., Ervik, M., Lam, F., Colombet, M., Mery, L., Pi\u00f1eros, M., Znaor, A., Soerjomataram, I., and Bray, F. (2020). Global Cancer Observatory: Cancer Today, International Agency for Research on Cancer. Available online: https:\/\/gco.iarc.fr\/today."},{"key":"ref_2","unstructured":"(2021, April 15). Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cancer."},{"key":"ref_3","unstructured":"(2020). GBD Results Tool, Institute for Health Metrics, University of Washington. Available online: http:\/\/ghdx.healthdata.org\/gbd-results-tool."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e180","DOI":"10.1016\/S2214-109X(19)30488-7","article-title":"Global burden of cancer attributable to infections in 2018: A worldwide incidence analysis","volume":"8","author":"Georges","year":"2020","journal-title":"Lancet Glob. Health"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"812e818","DOI":"10.1016\/j.drudis.2006.07.005","article-title":"Exploiting the enhanced permeability and retention effect for tumor targeting","volume":"11","author":"Iyer","year":"2006","journal-title":"Drug Discov. Today."},{"key":"ref_6","first-page":"891","article-title":"Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes","volume":"52","author":"Gabizon","year":"1992","journal-title":"Cancer Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1200\/JCO.1998.16.7.2445","article-title":"Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi\u2019s sarcoma: Results of a randomized phase III clinical trial","volume":"16","author":"Northfelt","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/annonc\/mdh097","article-title":"Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX\u00ae\/Doxil\u00ae) versus conventional doxorubicin for first-line treatment of metastatic breast cancer","volume":"15","author":"Wigler","year":"2004","journal-title":"Ann. Oncol."},{"key":"ref_9","first-page":"243","article-title":"Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes","volume":"7","author":"Harrington","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"6985","DOI":"10.1021\/acsnano.5b01324","article-title":"Positron emission tomography based elucidation of the enhanced permeability and retention effect in dogs with cancer using Copper-64 liposomes","volume":"9","author":"Hansen","year":"2015","journal-title":"ACS Nano"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.nantod.2012.10.010","article-title":"Odyssey of a cancer nanoparticle: From injection site to site of action","volume":"7","author":"Nichols","year":"2012","journal-title":"Nano Today"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"16014","DOI":"10.1038\/natrevmats.2016.14","article-title":"Analysis of nanoparticle delivery to tumours","volume":"1","author":"Wilhelm","year":"2016","journal-title":"Nat. Rev. Mater"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/nrc1893","article-title":"Drug penetration in solid tumours","volume":"6","author":"Minchinton","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/nrc1566","article-title":"Cancer nanotechnology: Opportunities and challenges","volume":"5","author":"Ferrari","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.addr.2015.01.002","article-title":"Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity","volume":"91","author":"Maeda","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1126\/scitranslmed.3003651","article-title":"Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile","volume":"4","author":"Hrkach","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"15127","DOI":"10.1073\/pnas.1309566110","article-title":"Correlating preclinical animal studies and human clinical trials of a multifunctional, polymeric nanoparticle","volume":"110","author":"Eliasof","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"11449","DOI":"10.1073\/pnas.1411393111","article-title":"Correlating animal and human phase Ia\/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA","volume":"111","author":"Zuckerman","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nrc2714","article-title":"Environment-mediated drug resistance: A major contributor to minimal residual disease","volume":"9","author":"Meads","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1021\/nl801736q","article-title":"Microfluidic platform for controlled synthesis of polymeric nanoparticles","volume":"8","author":"Karnik","year":"2008","journal-title":"Nano Lett."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.2174\/1381612826666200318170716","article-title":"Nanomedicines in Diagnosis and Treatment of Cancer: An Update","volume":"26","author":"Haider","year":"2020","journal-title":"Curr. Pharm. Des."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"109269","DOI":"10.1016\/j.apradiso.2020.109269","article-title":"99mTc-gallic-gold nanoparticles as a new imaging platform for tumor targeting","volume":"164","author":"Sakr","year":"2020","journal-title":"Appl. Radiat. Isot."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"119514","DOI":"10.1016\/j.ijpharm.2020.119514","article-title":"99mTc-Doxorubicin-loaded gallic acid-gold nanoparticles (99mTc-DOX-loaded GA-Au NPs) as a multifunctional theranostic agent","volume":"586","author":"Swidan","year":"2020","journal-title":"Int. J. Pharm."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/j.drudis.2017.05.004","article-title":"Carbon nanomaterials as versatile platforms for theranostic applications","volume":"22","author":"Kim","year":"2017","journal-title":"Drug Discov. Today"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.biomaterials.2013.10.078","article-title":"Magnetically engineered Cd-free quantum dots as dual-modality probes for fluorescence\/magnetic resonance imaging of tumors","volume":"35","author":"Ding","year":"2014","journal-title":"Biomaterials"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"17014","DOI":"10.1038\/natrevmats.2017.14","article-title":"Towards clinically translatable in vivo nanodiagnostics","volume":"2","author":"Park","year":"2017","journal-title":"Nat. Rev. Mater."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Hequet, E., Henoumont, C., Djouana Kenfack, V., Lemaur, V., Lazzaroni, R., Boutry, S., Vander Elst, L., Muller, R.N., and Laurent, S. (2020). Design, Characterization and Molecular Modeling of New Fluorinated Paramagnetic Contrast Agents for Dual 1H\/19F MRI. Magnetochemistry, 6.","DOI":"10.3390\/magnetochemistry6010008"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1039\/C8BM00175H","article-title":"Bio-inspired drug delivery systems: An emerging platform for targeted cancer therapy","volume":"6","author":"Gu","year":"2018","journal-title":"Biomater. Sci."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Ovais, M., Khalil, A.T., Ayaz, M., Ahmad, I., Nethi, S.K., and Mukherjee, S. (2018). Biosynthesis of Metal Nanoparticles via Microbial Enzymes: A Mechanistic Approach. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19124100"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.7150\/thno.22430","article-title":"Bioinspired multifunctional melanin-based nanoliposome for photoacoustic\/magnetic resonance imaging-guided efficient photothermal ablation of cancer","volume":"8","author":"Zhang","year":"2018","journal-title":"Theranostics"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.2174\/1389557516666160219122755","article-title":"Nanoemulsion: A novel eon in cancer chemotherapy","volume":"17","author":"Sahu","year":"2017","journal-title":"Mini Rev. Med. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.2174\/1381612822666161201143600","article-title":"Pharmacokinetic and pharmacodynamic features of nanoemulsion following oral, intravenous, topical and nasal route","volume":"23","author":"Choudhury","year":"2017","journal-title":"Curr. Pharm. Des."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.yrtph.2017.10.023","article-title":"Safety against nephrotoxicity in paclitaxel treatment: Oral nanocarrier as an effective tool in preclinical evaluation with marked in vivo antitumor activity","volume":"91","author":"Choudhury","year":"2017","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.ijbiomac.2018.06.190","article-title":"In vitro neuroprotective effects of naringenin nanoemulsion against b-amyloid toxicity through the regulation of amyloidogenesis and tau phosphorylation","volume":"118","author":"Md","year":"2018","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ijpharm.2013.10.055","article-title":"Improvement of cellular uptake, in vitro antitumor activity and sustained release profile with increased bioavailability from a nanoemulsion platform","volume":"460","author":"Choudhury","year":"2014","journal-title":"Int. J. Pharm."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jddst.2019.02.013","article-title":"Intranasal teriflunomide microemulsion: An improved chemotherapeutic approach in glioblastoma","volume":"51","author":"Gadhavea","year":"2019","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"S\u00e1nchez-L\u00f3pez, E., Guerra, M., Dias-Ferreira, J., Lopez-Machado, A., Ettcheto, M., Cano, A., Espina, M., Camins, A., Garcia, M.L., and Souto, E.B. (2019). Current applications of nanoemulsions in cancer therapeutics. Nanomaterials, 9.","DOI":"10.3390\/nano9060821"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1039\/D0CC00694G","article-title":"Fluorinated cryptophane-A and porphyrin-based theranostics for multimodal imaging-guided photodynamic therapy","volume":"56","author":"Zhang","year":"2020","journal-title":"Chem. Commun."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e1806444","DOI":"10.1002\/adma.201806444","article-title":"Versatile Theranostic Nanoemulsion for Architecture-Dependent Multimodal Imaging and Dually Augmented Photodynamic Therapy","volume":"31","author":"Zhang","year":"2019","journal-title":"Adv Mater."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"110848","DOI":"10.1016\/j.molliq.2019.04.125","article-title":"Near-infrared absorbing nanoemulsions as nonlinear ultrasound contrast agents for cancer theranostics","volume":"287","author":"Fernandes","year":"2019","journal-title":"J. Mol. Liq."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1080\/15384047.2017.1395118","article-title":"In Vitro and In Vivo evaluation of a novel folate-targeted theranostic nanoemulsion of docetaxel for imaging and improved anticancer activity against ovarian cancers","volume":"19","author":"Patel","year":"2018","journal-title":"Cancer Biol. Ther."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Silva, C.O., Pinho, J.O., Lopes, J.M., Almeida, A.J., Gaspar, M.M., and Reis, C. (2019). Current trends in cancer nanotheranostics: Metallic, polymeric, and lipid-based systems. Pharmaceutics, 11.","DOI":"10.3390\/pharmaceutics11010022"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/j.addr.2012.09.003","article-title":"Liposome imaging agents in personalized medicine","volume":"64","author":"Petersen","year":"2012","journal-title":"Adv. Drug Deliv. Rev"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1021\/mp800187d","article-title":"Tumor Targeting of Functionalized Quantum Dot\u2013 Liposome Hybrids by Intravenous Administration","volume":"6","author":"Tian","year":"2009","journal-title":"Mol. Pharmaceut."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"91","DOI":"10.7555\/JBR.31.20160146","article-title":"Multifunctional quantum dots and liposome complexes in drug delivery","volume":"32","author":"Wang","year":"2018","journal-title":"J. Biomed. Res."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Lamichhane, N., Udayakumar, T.S., D\u2019souza, W.D., Simone Ii, C.B., Raghavan, S.R., Polf, J., and Mahmood, J. (2018). Liposomes: Clinical Applications and Potential for Image- Guided Drug Delivery. Molecules, 23.","DOI":"10.3390\/molecules23020288"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez-Gonz\u00e1lez, R., Estelrich, J., and Busquets, M.A. (2016). Liposomes Loaded with Hydrophobic Iron Oxide Nanoparticles: Suitable T2 Contrast Agents for MRI. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17081209"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.colsurfb.2017.11.033","article-title":"Liposomally formulated phospholipid-conjugated novel near-infrared fluorescence probe for particle size effect on cellular uptake and biodistribution in vivo","volume":"161","author":"Xing","year":"2018","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/s42003-020-1016-z","article-title":"Liposomal nanotheranostics for multimode targeted in vivo bioimaging and near-infrared light mediated cancer therapy","volume":"3","author":"Prasad","year":"2020","journal-title":"Commun. Biol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"105576","DOI":"10.1016\/j.ejps.2020.105576","article-title":"Diagnostic and therapeutic evaluation of folate-targeted paclitaxel and vinorelbine encapsulating theranostic liposomes for non-small cell lung cancer","volume":"156","author":"Karpuz","year":"2021","journal-title":"Eur, J. Pharm. Sci."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"6122","DOI":"10.7150\/thno.42234","article-title":"BBB-penetrating codelivery liposomes treat brain metastasis of non-small cell lung cancer with EGFRT790M mutation","volume":"10","author":"Yin","year":"2020","journal-title":"Theranostics"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3389\/fphar.2020.00075","article-title":"Theranostic Attributes of Acoustic Cluster Therapy and Its Use for Enhancing the Effectiveness of Liposomal Doxorubicin Treatment of Human Triple Negative Breast Cancer in Mice","volume":"11","author":"Bush","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"15567","DOI":"10.1021\/acsomega.9b01924","article-title":"Nanobubble Liposome Complexes for Diagnostic Imaging and Ultrasound-Triggered Drug Delivery in Cancers: A Theranostic Approach","volume":"4","author":"Prabhakar","year":"2019","journal-title":"ACS Omega"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"5201","DOI":"10.1039\/c3tb20990c","article-title":"Recent trends in the use of lipidic nanoparticles as pharmaceutical carriers for cancer therapy and diagnostics","volume":"1","author":"Mssi","year":"2013","journal-title":"J. Mater. Chem. B"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.1166\/jbn.2014.1874","article-title":"Liposomes versus lipid nanoparticles: Comparative study of lipid-based systems as oryzalin carriers for the treatment of leishmaniasis","volume":"10","author":"Lopes","year":"2014","journal-title":"J. Biomed. Nanotechnol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0169-409X(01)00105-3","article-title":"Solid lipid nanoparticles: Production, characterization and applications","volume":"47","author":"Mehnert","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"12217","DOI":"10.1021\/acsami.6b16705","article-title":"Hydrophobic IR-780 Dye Encapsulated in cRGD-Conjugated Solid Lipid Nanoparticles for NIR Imaging-Guided Photothermal Therapy","volume":"9","author":"Kuang","year":"2017","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/1061186031000086108","article-title":"In vitro and in vivo study of solid lipid nanoparticles loaded with superparamagnetic iron oxide","volume":"11","author":"Peira","year":"2003","journal-title":"J. Drug Target."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1021\/bc100478k","article-title":"Novel method to label solid lipid nanoparticles with 64 Cu for positron emission tomography imaging","volume":"22","author":"Andreozzi","year":"2011","journal-title":"Bioconjug. Chem."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/adhm.201200006","article-title":"A novel solid lipid nanoparticle formulation for active targeting to tumor \u03b1v\u03b23 integrin receptors reveals cyclic RGD as a double-edged sword","volume":"1","author":"Shuhendler","year":"2012","journal-title":"Adv. Healthc. Mater."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/adhm.201200338","article-title":"Optically traceable solid lipid nanoparticles loaded with siRNA and paclitaxel for synergistic chemotherapy with in situ imaging","volume":"2","author":"Bae","year":"2013","journal-title":"Adv. Healthc. Mater."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2967\/jnumed.108.053561","article-title":"Quantum dots for in vivo small-animal imaging","volume":"50","author":"Bentolila","year":"2009","journal-title":"J. Nucl. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0939-6411(97)00107-0","article-title":"NMR relaxometric investigations of solid lipid nanoparticles (SLN) containing gadolinium (III) complexes","volume":"45","author":"Morel","year":"1998","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.actbio.2017.01.070","article-title":"Dualfunction nanostructured lipid carriers to deliver IR780 for breast cancer treatment: Anti-metastatic and photothermal anti-tumor therapy","volume":"53","author":"Li","year":"2017","journal-title":"Acta Biomater."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.colsurfb.2016.11.032","article-title":"Nearinfrared mediated quantum dots and paclitaxel co-loaded nanostructured lipid carriers for cancer theragnostic","volume":"150","author":"Olerile","year":"2017","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.2217\/nnm.12.170","article-title":"Formulation design and evaluation of quantum dot-loaded nanostructured lipid carriers for integrating bioimaging and anticancer therapy","volume":"8","author":"Hsu","year":"2013","journal-title":"Nanomedicine"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.apradiso.2016.11.002","article-title":"Synthesis, characterization and radiolabeling of folic acid modified nanostructured lipid carriers as a contrast agent and drug delivery system","volume":"119","author":"Ucar","year":"2017","journal-title":"Appl. Radiat. Isot."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ijpharm.2009.04.026","article-title":"Lipid nanocapsules: A new platform for nanomedicine","volume":"379","author":"Huynh","year":"2009","journal-title":"Int. J. Pharm."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.2217\/nnm-2018-0196","article-title":"Lactoferrin-tagged quantum dots-based theranostic nanocapsules for combined COX-2 inhibitor\/herbal therapy of breast cancer","volume":"13","author":"AbdElhamid","year":"2018","journal-title":"Nanomedicine"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.2147\/IJN.S29827","article-title":"A novel lipid-based nanomicelle of docetaxel: Evaluation of antitumor activity and biodistribution","volume":"7","author":"Ma","year":"2012","journal-title":"Int. J. Nanomed."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.7150\/thno.29820","article-title":"GSH-sensitive Pt(IV) prodrug-loaded phase-transitional nanoparticles with a hybrid lipid-polymer shell for precise theranostics against ovarian cancer","volume":"9","author":"Huang","year":"2019","journal-title":"Theranostics"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1080\/10717544.2017.1384518","article-title":"Synthetic lipoprotein as nano-material vehicle in the targeted drug delivery","volume":"24","author":"Zhang","year":"2017","journal-title":"Drug Deliv."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"9171","DOI":"10.1002\/anie.200903112","article-title":"Biomimetic nanocarrier for direct cytosolic drug delivery","volume":"48","author":"Zhang","year":"2009","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2217\/nnm.11.10","article-title":"Attenuation of nontargeted cell-kill using a high-density lipoprotein-mimicking peptide--phospholipid nanoscaffold","volume":"6","author":"Yang","year":"2011","journal-title":"Nanomedicine"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1002\/smll.201303842","article-title":"Nanoparticle-enabled, image-guided treatment planning of target specific RNAi therapeutics in an orthotopic prostate cancer model","volume":"10","author":"Lin","year":"2014","journal-title":"Small"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/s41467-018-03705-y","article-title":"Progress and challenges towards targeted delivery of cancer therapeutics","volume":"9","author":"Rosenblum","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.clim.2006.06.010","article-title":"The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer","volume":"121","author":"Daniels","year":"2006","journal-title":"Clin. Immunol."},{"key":"ref_78","first-page":"37","article-title":"Correlation of transferrin receptor expression with histologic grade and immunophenotype in chronic lymphocytic leukemia and non-Hodgkin\u2019s lymphoma","volume":"4","author":"Shah","year":"1990","journal-title":"Hematol. Pathol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/BF01600299","article-title":"Transferrin receptor expression in tumours of the human nervous system: Relation to tumour type, grading and tumour growth fraction","volume":"416","author":"Prior","year":"1990","journal-title":"Virchows Arch. A Pathol. Anat. Histopathol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/PAI.0b013e318209716e","article-title":"Differential expression of transferrin receptor (TfR) in a spectrum of normal to malignant breast tissues: Implications for in situ and invasive carcinoma","volume":"19","author":"Singh","year":"2011","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/sj.leu.2404958","article-title":"Recent advances in adult T-cell leukemia therapy: Focus on a new anti-transferrin receptor monoclonal antibody","volume":"22","author":"Callens","year":"2008","journal-title":"Leukemia"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"He, Q., Sun, X., Chu, C., Jiang, Q., Zhu, H., He, Y., Yue, T., Wang, R., Lei, P., and Shen, G. (2015). Endocytosis of a functionally enhanced GFP-tagged transferrin receptor in CHO cells. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0122452"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.addr.2012.11.001","article-title":"Structure and dynamics of drug carriers and their interaction with cellular receptors: Focus on serum transferrin","volume":"65","author":"Luck","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00232-014-9637-0","article-title":"Transferrin receptor-mediated endocytosis: A useful target for cancer therapy","volume":"247","author":"Tortorella","year":"2014","journal-title":"J. Membr. Biol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1517\/17425247.2013.837447","article-title":"Delivery of therapeutic nucleic acids via transferrin and transferrin receptors: Lipoplexes and other carriers","volume":"10","author":"Duzgunes","year":"2013","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1111\/j.1745-7254.2007.00623.x","article-title":"Antigen-binding characteristics of AbCD71 and its inhibitory effect on PHA-induced lymphoproliferation","volume":"28","author":"Lei","year":"2007","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s00262-005-0105-7","article-title":"The in vitro antitumor effect and in vivo tumor-specificity distribution of human-mouse chimeric antibody against transferrin receptor","volume":"55","author":"Qing","year":"2006","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.cellimm.2010.03.008","article-title":"Viral specific cytotoxic T cells inhibit the growth of TfR-expressing tumor cells with antibody targeted viral peptide\/HLA-A2 complex","volume":"263","author":"Li","year":"2010","journal-title":"Cell Immunol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/mt.2008.266","article-title":"Targeting hypoxia-inducible factor-1alpha with Tf-PEI-shRNA complex via transferrin receptor-mediated endocytosis inhibits melanoma growth","volume":"17","author":"Liu","year":"2009","journal-title":"Mol. Ther."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Ye, Q., Hu, H., Wang, Z., Lu, T., Hu, Z., Zeng, X., Zhang, S., Liu, J., Lei, P., and Wang, C.Y. (2012). Generation and functional characterization of the anti-transferrin receptor single-chain antibody-GAL4 (TfRscFv-GAL4) fusion protein. BMC Biotechnol., 12.","DOI":"10.1186\/1472-6750-12-91"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"119","DOI":"10.7150\/ntno.41741","article-title":"Establishment of a hTfR mAb-functionalized HPPS theranostic nanoplatform","volume":"4","author":"He","year":"2020","journal-title":"Nanotheranostics"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1096\/fj.09-139865","article-title":"RGD peptide functionalized and reconstituted high-density lipoprotein nanoparticles as a versatile and multimodal tumor targeting molecular imaging probe","volume":"24","author":"Chen","year":"2010","journal-title":"FASEB J."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"10410","DOI":"10.1021\/acs.chemrev.5b00193","article-title":"Gold Nanomaterials at Work in Biomedicine","volume":"115","author":"Yang","year":"2015","journal-title":"Chem. Rev."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"6484","DOI":"10.1039\/C6NR01339B","article-title":"Coloured cornea replacements with anti-infective properties: Expanding the safe use of silver nanoparticles in regenerative medicine","volume":"8","author":"Alarcon","year":"2016","journal-title":"Nanoscale"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.addr.2011.06.003","article-title":"Oxide and hybrid nanostructures for therapeutic applications","volume":"63","author":"Chandra","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_96","first-page":"33","article-title":"Lipid-coated gold nanocomposites for enhanced cancer therapy","volume":"10","author":"Kang","year":"2015","journal-title":"Int. J. Nanomed."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40580-014-0023-5","article-title":"Multiplexed detection of various breast cancer cells by perfluorocarbon\/quantum dot nanoemulsions conjugated with antibodies","volume":"1","author":"Bae","year":"2014","journal-title":"Nano Converg."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"9761","DOI":"10.1021\/nn403258w","article-title":"Gold Nanocrystal Labeling Allows Low-Density Lipoprotein Imaging from the Subcellular to Macroscopic Level","volume":"7","author":"Allijn","year":"2013","journal-title":"ACS Nano"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.biomaterials.2015.10.004","article-title":"Gold conjugate-based liposomes with hybrid cluster bomb structure for liver cancer therapy","volume":"74","author":"Zhang","year":"2016","journal-title":"Biomaterials"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/nnano.2010.235","article-title":"Freestanding palladium nanosheets with plasmonic and catalytic properties","volume":"6","author":"Huang","year":"2011","journal-title":"Nat. Nanotechnol."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Adams, C.P., Walker, K.A., Obare, S.O., and Docherty, K.M. (2014). Size-Dependent Antimicrobial Effects of Novel Palladium Nanoparticles. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0085981"},{"key":"ref_102","first-page":"15677","article-title":"A hybrid lipid membrane coating \u201cshape-locks\u201d silver nanoparticles to prevent surface oxidation and silver ion dissolution","volume":"10","author":"Miesen","year":"2020","journal-title":"RCS Adv."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.cll.2012.01.001","article-title":"Gold nanoparticle-mediated detection of circulating cancer cells","volume":"32","author":"Bhattacharyya","year":"2012","journal-title":"Clin. Lab. Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"10505","DOI":"10.1021\/acsami.8b21609","article-title":"Combinational Effects of Active Targeting, Shape, and Enhanced Permeability and Retention for Cancer Theranostic Nanocarriers","volume":"11","author":"Chen","year":"2019","journal-title":"ACS Appl. Mater Interfaces"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jconrel.2016.11.015","article-title":"To Exploit the Tumor Microenvironment: Since the Epr Effect Fails in the Clinic, What Is the Future of Nanomedicine?","volume":"244","author":"Danhier","year":"2016","journal-title":"J. Control. Release"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/nbt.3330","article-title":"Principles of Nanoparticle Design for Overcoming Biological Barriers to Drug Delivery","volume":"33","author":"Blanco","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"17247","DOI":"10.1073\/pnas.1305000110","article-title":"Mammalian Cells Preferentially Internalize Hydrogel Nanodiscs over Nanorods and Use Shape-Specific Uptake Mechanisms","volume":"110","author":"Agarwal","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1517\/17425247.2014.950564","article-title":"The Importance of Nanoparticle Shape in Cancer Drug Delivery","volume":"12","author":"Truong","year":"2015","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1021\/bm5017805","article-title":"Self-Assembling Polymer Micelle\/Clay Nanodisk\/ Doxorubicin Hybrid Injectable Gels for Safe and Efficient Focal Treatment of Cancer","volume":"16","author":"Nagahama","year":"2015","journal-title":"Biomacromolecules"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/adhm.201500827","article-title":"Ruthenium-Containing Block Copolymer Assemblies: Red- Light-Responsive Metallopolymers with Tunable Nanostructures for Enhanced Cellular Uptake and Anticancer Phototherapy","volume":"5","author":"Sun","year":"2016","journal-title":"Adv. Healthc. Mater."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1804227","DOI":"10.1002\/adfm.201804227","article-title":"Red-Light- Controlled Release of Drug\u2212Ru Complex Conjugates from Metallopolymer Micelles for Phototherapy in Hypoxic Tumor Environments","volume":"28","author":"Sun","year":"2018","journal-title":"Adv. Funct. Mater."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.jconrel.2013.09.013","article-title":"Factors Controlling the Pharmacokinetics, Biodistribution and Intratumoral Penetration of Nanoparticles","volume":"172","author":"Ernsting","year":"2013","journal-title":"J. Control. Release"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s10404-012-1024-5","article-title":"The Influence of Size, Shape and Vessel Geometry on Nanoparticle Distribution","volume":"14","author":"Tan","year":"2013","journal-title":"Microfluid. Nanofluid."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Carregal-Romero, S., Plaza-Garc\u00eda, S., Pi\u00f1ol, R., Murillo, J.L., Ruiz-Cabello, J., Padro, D., Mill\u00e1n, A., and Ramos-Cabrer, P. (2018). MRI Study of the Influence of Surface Coating Aging on the In Vivo Biodistribution of Iron Oxide Nanoparticles. Biosensors, 8.","DOI":"10.20944\/preprints201811.0135.v1"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"14153","DOI":"10.1039\/C8NR03084G","article-title":"PEG-copolymer-coated iron oxide nanoparticles that avoid the reticuloendothelial system and act as kidney MRI contrast agents","volume":"10","author":"Puigivila","year":"2018","journal-title":"Nanoscale"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"6169","DOI":"10.1038\/ncomms7169","article-title":"Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity","volume":"6","author":"Majumder","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.ijpharm.2018.01.016","article-title":"Recent trends of nanomedicinal approaches in clinics","volume":"538","author":"Dilnawaz","year":"2018","journal-title":"Int. J. Pharm."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/anie.200802585","article-title":"Nanomedicine\u2014Challenge and perspectives","volume":"48","author":"Riehemann","year":"2009","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nrc.2016.108","article-title":"Cancer nanomedicine: Progress, challenges and opportunities","volume":"17","author":"Shi","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.nano.2015.12.377","article-title":"Comparison of complement activation-related pseudoallergy in miniature and domestic pigs: Foundation of a validatable immune toxicity model","volume":"12","author":"Jackman","year":"2016","journal-title":"Nanomedicine"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.bbrc.2015.06.177","article-title":"Complement activation as a bioequivalence issue relevant to the development of generic liposomes and other nanoparticulate drugs","volume":"468","author":"Szebeni","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"790","DOI":"10.3389\/fphar.2018.00790","article-title":"Current trends and challenges in the clinical translation of nanoparticulate nanomedicines: Pathways for translational development and commercialization","volume":"9","author":"Hua","year":"2018","journal-title":"Front. Pharmacol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"15175","DOI":"10.1039\/C5NR03119B","article-title":"A challenge for theranostics: Is the optimal particle for therapy also optimal for diagnostics?","volume":"7","author":"Dreifuss","year":"2015","journal-title":"Nanoscale"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.bbrc.2015.08.023","article-title":"Regulatory aspects on nanomedicines","volume":"468","author":"Sainz","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2217\/17435889.2.2.143","article-title":"Regulatory issues surrounding nanomedicines: Setting the scene for the next generation of nanopharmaceuticals","volume":"2","author":"Gaspar","year":"2007","journal-title":"Nanomedicine"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/nyas.12403","article-title":"Nanomedicines: Addressing the scientific and regulatory gap","volume":"1313","author":"Tinkle","year":"2014","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.addr.2016.04.025","article-title":"Challenges and strategies in anti-cancer nanomedicine development: An industry perspective","volume":"108","author":"Hare","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"228","DOI":"10.3389\/fphar.2018.00228","article-title":"Risk assessment and risk minimization in nanomedicine: A need for predictive, alternative, and 3Rs strategies","volume":"9","author":"Accomasso","year":"2018","journal-title":"Front. Pharmacol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1080\/17425247.2016.1244187","article-title":"Nanoparticle-based drug delivery systems: A commercial and regulatory outlook as the field matures","volume":"14","author":"Ragelle","year":"2017","journal-title":"Expert Opin. Drug Deliv."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/13\/6\/840\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:11:37Z","timestamp":1760163097000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/13\/6\/840"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,7]]},"references-count":129,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,6]]}},"alternative-id":["pharmaceutics13060840"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics13060840","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,7]]}}}